PDGFRA and gastrointestinal stromal tumor: Avapritinib was approved in 2020 by the FDA for gastrointestinal stromal tumors with a mutation in exon 18 PDGFRA (NAVIGATOR study) [69], a multicenter, single-arm, open-label trial.